Menna Fouda, Founder & Medical Education Lead – Understanding Cancer with Dr Menna, shared on LinkedIn:
“What should oncologists know about mRNA cancer vaccines? | ESMO Congress 2026
One of the exciting areas of cancer research discussed at ESMO 2026 in Madrid is the potential of mRNA vaccines to transform cancer immunotherapy.
Unlike traditional vaccines designed to prevent infections, therapeutic cancer vaccines aim to train the immune system to recognise and attack tumour cells by targeting tumour-specific mutations, including passenger mutations.
Key takeaways for oncologists:
- Personalised immunotherapy: mRNA technology can be used to encode tumour antigens and stimulate a targeted immune response.
- Beyond immunotherapy-responsive tumours: Research is exploring whether cancer vaccines could extend the benefits of immunotherapy to cancers that are currently less responsive.
- Durable immune responses: The ultimate goal is to generate sustained antitumour immunity that may delay recurrence or, potentially, prevent disease progression.
- From discovery to clinical application: Advances in antigen discovery, vaccine design, manufacturing and immune monitoring are helping accelerate clinical translation.
The future challenge: Can we achieve substantial and durable immunity across a broader range of cancers?
These approaches remain an evolving area of research, and their clinical benefit will need to be established through robust clinical trials.”
Stay informed on the latest research, insights, and discussions from ESMO 2026 with OncoDaily.